Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are ...

Cardiovascular effectiveness was observed, largely independent of age, in a cohort of older patients with type 2 diabetes.

A new study found that patients with type 2 diabetes treated with GLP-1 receptor agonists and sodium-glucose cotransporter-2 ...

A major new study finds that certain diabetes medications, including GLP-1 and SGLT2 inhibitors, may be linked to a reduced ...

Loss of skeletal muscle mass is a known risk factor for falls. Researchers from the University of Tsukuba conducted a 5-yr follow-up study on 471 patients with type 2 diabetes and found that ...

A new study suggests that two widely used Type 2 diabetes medications—GLP-1 receptor agonists and SGLT2 inhibitors—may help reduce the risk of Alzheimer’s disease and related dementias.

The study supports prior research that found the same thing.

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

Medications designed to treat diabetes by lowering blood sugar levels, like Ozempic, continue to turn up added benefits, and ...

Two studies suggested the diabetes/weight-loss drug may have a beneficial side effect—but more work is needed to confirm this.

Certain diabetes medications, particularly SGLT2 inhibitors and GLP-1 receptor agonists, are associated with weight reduction, which may contribute to muscle mass loss and, consequently ...